Sterling Winthrop
Executive Summary
Enters agreement with Edmonton, Alberta-based Biomira to license existing and future antibodies for cancer indications. The non-equity deal grants Sterling Winthrop an option to the antibodies on a product-by-product basis in exchange for royalties. With the signing of the deal, Sterling Winthrop exercises its option on Biomira's 174 antibody, which is in preclinical development for use against squamous cell carcinomas of the cervix, lung, and head and neck.